Tesofensine is a triple reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's. It was found to cause significant weight loss by reducing appetite and increasing satiety. It's now being developed specifically for obesity.
Appetite Regulation
Peptides mimic satiety hormones, reducing hunger signals from the brain.
Quickstart Highlights
- Dosage: 0.25-0.5mg
- Frequency: Daily
- Administration: Oral capsule
- Cycle length: 12-24 weeks
Dosing Plan
| Weeks | Dose | Units |
|---|---|---|
| Starting | 0.25mg daily | Morning with food |
| Maintenance | 0.5mg daily | Morning with food |
How This Works
Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing their concentrations in the synaptic cleft. This affects appetite-regulating centers in the hypothalamus, reducing hunger and increasing satiety. The norepinephrine effects may also increase metabolic rate. Unlike stimulants, it has a more balanced effect on all three neurotransmitters.
Mechanism of Action
How Tesofensine Works in Your Body
Peptide Administered
Enters bloodstream and travels to target receptors
Brain Signaling
Binds to GLP-1 receptors in the hypothalamus
Appetite Reduced
Signals satiety — you feel full sooner
Fat Metabolism
Body shifts to burning stored fat for energy
Benefits & Side Effects
Potential Benefits
- Significant weight loss (10%+ in trials)
- Reduced appetite and food intake
- Increased satiety after meals
- Potential metabolic rate increase
- Oral convenience
- Once-daily dosing
Potential Side Effects
- Increased heart rate
- Dry mouth
- Constipation
- Insomnia
- Mood changes
- Potential for abuse (dopamine effects)
- Not suitable for those with CV or psychiatric conditions
Good to know
- NOT a peptide - small molecule triple reuptake inhibitor.
- Inhibits reuptake of serotonin, norepinephrine, and dopamine.
- Discovered weight loss effects during Parkinson's trials.
- May cause significant weight loss (10%+ body weight).
- NOT FDA approved - available through research sources.
- Potential for cardiovascular and CNS effects.
- Not recommended for those with heart conditions or anxiety.
Community Insights
Summarised from 3 sourcesTesofensine is a triple reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's. It was found to cause significant weight loss by reducing appetite and increasing satiety. It's now being developed specifically for obesity. Triple monoamine reupta
Common Dosages Reported
- 0.25-0.5mg Daily
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Strong Potential for Weight Loss and Hunger Control
One individual highlighted Tesofensine's potency for weight loss, mentioning its success in clinical trials where participants lost significant body fat. They described it as a sophisticated compound that effectively modulates neurotransmitters to control hunger.
Effective Stimulant with Long Half-Life
A user reported that Tesofensine is an effective stimulant that is often overlooked. They noted it functions as a triple reuptake inhibitor with a very long half-life, providing sustained energy and appetite suppression.
Tesofensine Introduced as Premier Fat Loss Agent
An industry expert and forum contributor described Tesofensine as the 'ultimate fat loss peptide.' They published a detailed educational video and discussion thread to introduce its availability and benefits to the community.
New Fat-Loss Product Availability
A representative for a domestic supplier introduced Tesofensine as an exciting new product for fat loss. They noted that it is becoming a popular alternative for individuals looking beyond traditional fat-burning protocols.
Tesofensine Recommendation for Weight Management
A user recommended Tesofensine (specifically the Pharmacom brand) as a high-quality option for those looking to utilize this compound for weight management. They highlighted its availability through trusted domestic suppliers.
Immediate Mood Boost
A user reported experiencing an immediate mood boost after starting the peptide. They intended to wait for appetite suppression but noted concerns about potential interactions with stimulants like yohimbine.
Quick Appetite Suppression and Insomnia
A user reported that appetite suppression began on the first day of use. However, they experienced significant difficulty sleeping and advised against combining the peptide with high-dose caffeine or yohimbine due to prolonged adrenaline effects.
Tesofensine and Tesamorelin Combination for Weight Loss
A user reported that the combination of Tesofensine, which acts as a serotonin and dopamine reuptake inhibitor, and Tesamorelin is often used for weight loss with very good results. They noted that Tesofensine is effective specifically for weight loss and suppression of appetite.
Tesofensine for Appetite Suppression Support
A user recommended adding Tesofensine to a Retatrutide regimen as an alternative to increasing the Retatrutide dosage. They suggested it can be used specifically to provide further appetite suppression when other weight loss peptides reach common dosing limits.
Positive Mood and Energy Improvements
A user reported positive experiences with the peptide, noting a significant improvement in mood and a reduction in fatigue. They experienced increased energy levels and a greater drive to complete tasks.
Concerns Regarding Insomnia and Anxiety
A user cautioned against using this peptide for weight loss due to potential side effects. They suggested it can cause insomnia and lead to feelings of anxiety or overstimulation.
Tesofensine for AuDHD (Initial Experience)
A user with AuDHD reported that tesofensine initially provided significant improvements in executive function, emotional regulation, and sensory processing. They noted it felt more sustainable than traditional stimulants, though they emphasized the importance of managing the long half-life to avoid insomnia.
Update: Tesofensine for AuDHD (Diminishing Returns)
In a follow-up report, the same user noted that the positive effects of tesofensine diminished significantly after a few months. They experienced a return of anxiety, depressive symptoms, and executive dysfunction, concluding that the peptide did not maintain its initial efficacy for their neurodivergence.
Significant dry mouth and insomnia at 0.25mg
A user experienced extreme dry mouth and significant sleep disturbances shortly after beginning a 0.25mg daily regimen. While the drug effectively suppressed their appetite, the side effects were severe enough to cause discomfort.
Two-week experience with appetite suppression
After two weeks of daily morning use, a user reported consistent appetite suppression and a noticeable reduction in stomach capacity. They noted that the effects were steady throughout the day when taken early in the morning.
Tesofensine used for maintenance during GLP-1 pause
A user reported using tesofensine during a maintenance phase to manage appetite while pausing tirzepatide. They found the compound effective for weight management and appetite suppression, allowing them to maintain their goal weight without the stronger hunger signals typical of a GLP-1 break.
No discussion yet — be the first.
No notes yet — be the first.